Say bye-bye to winter worries with these divinefoods | WeForNews | Latest News, Blogs Say bye-bye to winter worries with these divinefoods – WeForNews | Latest News, Blogs
Connect with us

Health

Say bye-bye to winter worries with these divinefoods

Published

on

Superfoods-wefornews
file name

From humble turmeric powder and Bugs Bunny’s favorite carrots to adding oodles of dark chocolate to your diet, you can keep yourself fit and healthy this winter season by stocking up some easy-to-find super foods.

Sonia Narang, nutrition expert, Oriflame India, lists out some divine foods to fight winter blues:

* Maca root – Ashwagandha root is a herb of the ages. It is the ginseng of ayurvedic medicine, the traditional medicine of India and is considered an adaptogen — a term used to describe herbs that improve physical energy and athletic ability, increase immunity and help fight the infections and increase sexual capacity and fertility.

* Turmeric – It has a global reputation for boosting immunity. It acts as an anti-bacterial, anti-fungal and anti-viral agent and helps in boosting the overall functioning of our immune system. It can be taken in warm milk for its best benefits.

*Chia seeds – These powerful seeds are an amazing source of protein, omega 3 fatty acids and important minerals. It is best taken when soaked in water overnight.

*Carrots – This root vegetable contains high amounts of beta carotene which the body converts into Vitamin A. Vitamin A is a key nutrient in immune function, helping to protect against infection and reduce the risk and duration of respiratory illness by keeping our lungs healthy. It is an excellent food to protect the skin from ageing.

*Garlic- It has been used for thousands of years in the treatment of illness and disease. Its compound called allicin has potent medicinal properties which helps combat sickness, cold and cough.

*Fennel – This licorice-tasting winter vegetable offers more than just a unique tang. Fennel is low in calories yet high in phytonutrient anethole, which may help boost the immune response.

*Beetroot – It is packed with beneficial phytochemicals and antioxidants which protect the immune system by fighting off destructive free radicals, which harm healthy cells and their DNA.

* Dark chocolate – Cocoa-based dark chocolate is one of the best natural sources of antioxidants, iron, magnesium and zinc. Zinc, an important trace mineral, is important for immune function.

wefornews bureau

Health

Russia to begin COVID-19 vaccine production within 2 weeks

Published

on

By

COVID-19 Vaccine

MOSCOW, Aug. 12 : Russia will start the production of its COVID-19 vaccine within two weeks, the country’s health minister Mikhail Murashko said Wednesday.

“First of all, the production facilities in Russia will be oriented towards the domestic market, to meet the need of our citizens,” Murashko said during a news conference.

Russia will offer the vaccine to other countries when it has sufficient amounts, the minister said, adding that foreign nations’ doubts about the effectiveness of the vaccine are unfounded.

The platform where the vaccine was created has been thoroughly studied and its authors have accumulated a sufficient amount of scientific data to guarantee its safety, he added.

The world’s first registered vaccine against the novel coronavirus was announced by President Vladimir Putin on Tuesday during an online meeting with government officials.

The vaccine, named Sputnik V, was developed by the Gamaleya National Center of Epidemiology and Microbiology, alongside the Russian Direct Investment Fund.

Russia plans to produce at least five million doses of the vaccine a month from December through January, according to Alexander Gintsburg, director of the Gamaleya National Research Center.

He said that the center is also preparing documents to obtain permission to test the vaccine on children.

The vaccine for children will be the same as the one for adults, but will likely be administered in a different dosage, requiring additional testing, Gintsburg added.

So far, Russia has tallied a total of 902,701 COVID-19 cases, including 15,260 deaths and 710,298 recoveries.

Continue Reading

Health

US strikes $1.5bn deal for 100mn doses of Moderna Covid vax

The US government has announced that consistent with its commitment to free access to Covid-19 vaccines, Americans will receive mRNA-1273 at no cost for the vaccine itself.

Published

on

By

Covid 19 Vaccine

New York, Aug 12 : The US government has entered into a $1.5 billion deal with biotechnology company Moderna for the manufacturing and delivery of 100 million doses of its potential Covid-19 vaccine, mRNA-1273.

With the previous award of up to $955 million for the development of the vaccine to licensure, the new announcement brings the US government’s commitments for early access to mRNA-1273 to up to $2.48 billion, Moderna said on Tuesday.

Under the terms of the agreement, the US government will also have the option to purchase up to an additional 400 million doses of mRNA-1273 from Moderna.

The US government has announced that consistent with its commitment to free access to Covid-19 vaccines, Americans will receive mRNA-1273 at no cost for the vaccine itself.

As is customary with all government-purchased vaccines, healthcare professionals could charge for the cost of administering the vaccine.

“We appreciate the confidence of the US government in our mRNA vaccine platform and the continued support,” Stephane Bancel, Moderna’s Chief Executive Officer, said in a statement.

A Phase 3 study of mRNA-1273, being conducted in collaboration with the US National Institutes of Health (NIH) and Biomedical Advanced Research and Development Authority (BARDA), began on July 27.

BARDA is part of the office of the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS).

Enrollment for the study is on track to complete in September, Moderna said.

Continue Reading

Health

Covid cases haven’t yet peaked or even plateaued: AIIMS Dir

The remarks come at a time when the infections are racing ahead with the country adding at least a lakh new cases every two days.

Published

on

Randeep Guleria AIIMS

New Delhi: All India Institute of Medical Sciences (AIIMS) Director Randeep Guleria, one of India’s leading medical experts, has asserted that the coronavirus cases in the country have not yet hit their peak or even plateaued.

The remarks come at a time when the infections are racing ahead with the country adding at least a lakh new cases every two days. It has logged more than 23 lakh cases and over 46,000 deaths so far since the first case on January 30.

“These are trying times. It has tested the resilience of the nation. We have not reached the peak or started plateauing as far as cases are concerned,” Guleria, who is also the part of a core team monitoring the pandemic, said.

Shedding light on the vaccine development, he said that India has an advantage because it makes almost 60 per cent of the world’s vaccines.

“We have the capacity to manufacture a large number of vaccines and that is the commitment that the government and manufacturers have given — that we will be able to upscale our manufacturing capacity not only for our own country but for the entire world,” he added.

Three vaccine candidates are in different stages of human clinical trials in India — one developed by University of Oxford by Pune’s Serum Institute of India, the other inactivated virus vaccine by Bharat biotech and the third DNA vaccine by Zydus Cadila.

The country’s top pulmonologist further said that the vaccine development has moved so rapidly because of the collaborative work between various countries. “What the pandemic has shown is the resilience that the world has and the way researchers, manufactures and industries can come together to overcome any hardship we face as a planet.”

Guleria, however, advised caution with regards to the Russian vaccine, being touted as the world’s first coronavirus vaccine. Elaborating on the safety aspect, he said that the issue would be just to make sure that the vaccine is “safe and efficacious”.

“Any vaccine that is tried in a large number of people who are elderly or have comorbidities, safety is the most important thing and should of course be efficacious in terms of what degree of protection does it give and how long the protection lasts,” the AIIMS Director said.

The comments come in the backdrop of Russian President Vladimir Putin’s announcement about the approval of the coronavirus vaccine for public use. It is, however, marred by controversies and is yet to complete the final trials.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.